fda compounding semaglutide crackdown november 2025 Millions of Americans are turning to GLP-1 medications, but a growing market of unapproved compounded knockoffs is creating serious patient safety risks. Today, PSM released A Call to Action: Restoring and Strengthening Medscape | The FDA has

Figure 1 A summarized presentation of various genes involved in PD and their respective mechanisms of action is given in Table 1

doi: 10.1271/bbb.66.702

He noted that while the study was relatively short term, the effect was clear and said the once-daily pill could be particularly attractive as an option for people living with diabetes not wanting injectable therapy

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Finalmente, la obesidad se asocia con peor respuesta a la farmacoterapia de la PsO (Tabla S1 ver material adicional)29,30